Biogen Inc. (BIIB) Stock Price & How to Invest
Last updated November 2026
Short answer
Biogen (BIIB) is a large-cap neuroscience biotech in transition: legacy multiple sclerosis and Spinraza revenue are eroding while it bets on the Alzheimer's drug Leqembi, rare-disease franchises, the roughly $5.6 billion Apellis acquisition and an immunology pipeline led by lupus programs to restart growth. You would own it as a turnaround story that still trades at a below-market forward multiple (about 14 times as of October 2026), though the shares have already risen about 33% in 2026.
BIIB stock price
As of 2026-11-16, Biogen Inc. (BIIB) last closed at $251.65, up 52.8% over the past year. Over the past 52 weeks it has traded between $164.42 and $254.87.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Biogen Inc.'s investor relations page. Walnut is informational, not investment advice.
BIIB key stats
At $251.65 on November 16, 2026, Biogen Inc. (BIIB) has a market cap of $37.2B and a P/E of 108.9 on trailing earnings (15.5 on forward earnings).
- Market cap
- $37.2B
- P/E (trailing)
- 108.9
- P/E (forward)
- 15.5
- EPS (trailing 12 months)
- $2.31
- Price to book
- 2.0
- Beta
- 0.09
Market cap, P/E and yield are measured at the $251.65 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Biogen Inc. (BIIB)?
The last two weeks for Biogen Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- BIIB closed at $251.65 on November 16, 2026, down 1.3% over the past five trading days (from $254.87).
- On November 9, 2026, Piper Sandler raised its target to $305.00 from $245.00 (Overweight).
Biogen Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Biogen Inc. (BIIB) latest quarter
Biogen reported revenue of $2.8 billion for Q3 2026, up 11% from a year earlier (Biogen, Oct 28, 2026).
Source: Biogen Q3 2026 results, Oct 28, 2026. Full earnings breakdown
What does Biogen Inc. (BIIB) do?
Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience. Its historic core is multiple sclerosis (Tysabri, Tecfidera, Vumerity), and it co-developed the spinal muscular atrophy drug Spinraza with Ionis. Its growth story now centers on Leqembi, the Alzheimer's antibody it markets with partner Eisai, alongside newer rare-disease products Skyclarys (Friedreich's ataxia) and Qalsody (ALS). In 2026 it closed the roughly $5.6 billion acquisition of Apellis Pharmaceuticals, adding the retinal drug Syfovre for geographic atrophy and Empaveli for rare blood and kidney diseases. Beyond neuroscience it is pushing into immunology, where litifilimab (which holds FDA Breakthrough Therapy Designation in cutaneous lupus) reported sustained 52-week skin improvement in the AMETHYST study in late September 2026.
The investment picture is a classic biotech transition. Legacy MS sales face generic and biosimilar erosion (Biogen guided MS revenue excluding Vumerity down a mid-teen percentage in 2026). Against that, Leqembi is scaling (Q1 2026 in-market sales up 74 percent year over year), Apellis products are now consolidated, and management is using cost discipline to defend earnings. Trailing revenue is about $10.0 billion, and analysts model about $10.4 billion for 2026, above the roughly $9.9 billion of 2025. Second-quarter 2026 revenue grew about 3% year over year and non-GAAP EPS of $3.60 beat the roughly $2.03 consensus by a wide margin, the fourth beat in a row.
The stock has rerated with that execution. As of October 16, 2026 BIIB closed near $236, up about 33% year to date and about 66% over one year, just under its 52-week high of about $241, after J.P. Morgan upgraded it to Overweight on October 12 ahead of a slate of pipeline readouts. Third-quarter results are due October 28, 2026, with consensus EPS of about $2.00 on revenue near $2.63 billion.
What's driving Biogen Inc. (BIIB)?
1. Leqembi Alzheimer's ramp
Leqembi is the single biggest swing factor, with Q1 2026 worldwide in-market sales around $168 million, up roughly 74 percent year over year across the US, Japan, and China. Real-world data showing about 78 percent of patients still on therapy at 18 months supports the durability of the franchise. Subcutaneous maintenance dosing (IQLIK) could broaden adoption if uptake and reimbursement continue to build.
2. Rare-disease and new-product portfolio
Skyclarys (Friedreich's ataxia) grew roughly 22 percent year over year to about $151 million in Q1 2026, and high-dose Spinraza was approved to defend the SMA franchise against competition. The Apellis deal adds Syfovre for geographic atrophy and Empaveli for PNH and rare kidney diseases, products that together generated roughly $689 million in 2025. These launches are the intended replacements for shrinking legacy sales.
3. Immunology and late-stage readouts
Biogen is expanding beyond neuroscience with lupus and kidney programs. Litifilimab showed sustained improvement in cutaneous lupus at 52 weeks in the AMETHYST study, and further lupus data are expected, which was a stated reason for J.P. Morgan's October 2026 upgrade. Positive late-stage data would add a new growth leg; a miss would leave the story more dependent on Leqembi.
4. Cost discipline and cash-funded M&A
Biogen has leaned on operating-expense reductions to protect earnings, delivering non-GAAP EPS of about $3.57 in Q1 2026 and $3.60 in Q2, both well ahead of consensus. It funded the Apellis purchase with cash on hand plus bank debt, leaving about $1.3 billion of cash against about $8.4 billion of debt at mid-2026, while generating about $2.9 billion of operating cash flow over the last twelve months. The strategy is to convert a mature cash-generating base into growth through selective dealmaking.
What are the risks to Biogen Inc. (BIIB)?
The legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars. Leqembi faces direct competition from Eli Lilly's Kisunla and lingering questions about diagnostic access, infusion logistics, and payer coverage, so its ramp could disappoint. Large acquisitions like Apellis add integration and execution risk, raised debt to about $8.4 billion, and carry contingent value payments tied to Syfovre sales that create uncertain future costs; GAAP net income over the last twelve months was only about $835 million, which is why the trailing P/E sits near 42. Biotech pipelines carry binary clinical and regulatory outcomes, and the upcoming lupus readouts are exactly that kind of event. After a 66% one-year rally to near the 52-week high, the share price leaves less room for disappointment than the old discount did, and consensus still expects 2026 EPS of about $12.53, down about 18% from 2025.
What is the Biogen Inc. (BIIB) forecast?
32 analysts publish price targets on BIIB, averaging $268.26 as of November 2026, or +6.6% against the $251.65 share price on November 16, 2026. The published targets run from $175.00 to $350.00, a moderate spread, and the ratings split 25 buy, 10 hold, 1 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full BIIB forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is BIIB a buy or a sell?
We give no verdict on Biogen Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Leqembi Alzheimer's ramp. Leqembi is the single biggest swing factor, with Q1 2026 worldwide in-market sales around $168 million, up roughly 74 percent year over year across the US, Japan, and China. The most optimistic published target, $350.00, assumes this works close to its best case.
The case against. The legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars. The most pessimistic target, $175.00, is roughly what BIIB is worth if this bites instead.
Read the full bull and bear case on BIIB, including what would have to change to break either one. Walnut is not an investment adviser.
Has Biogen Inc. (BIIB) split its stock?
No. Biogen Inc. (BIIB) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Biogen Inc. (BIIB) valued?
Market cap, P/E and dividend yield at today's price are in the BIIB key stats above. The business figures below come from Biogen Inc.'s reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$10.0B
- Q2 2026 revenue growth: ~3% YoY
- Q2 2026 non-GAAP EPS: ~$3.60 (vs ~$2.03 est.)
- Net income (TTM): ~$835M (~8% margin)
As of October 2026: Biogen trades at about 14 times forward earnings, still below many large-cap drugmakers, while the trailing P/E near 42 reflects GAAP charges tied to the Apellis deal rather than the underlying run rate. Analysts expect 2026 EPS of about $12.53 and a rebound to about $16.52 in 2027, and the average price target of about $244 sits only slightly above the current price after the rally. The October 28 report (consensus EPS about $2.00) is the next check on whether the beats continue.
Which ETFs hold Biogen Inc. (BIIB)?
What themes does Biogen Inc. (BIIB) fit?
These are the investment theses BIIB naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.
Who competes with Biogen Inc. (BIIB)?
Alzheimer's and neurology
Eli Lilly (Kisunla/donanemab) is the most direct rival to Leqembi in Alzheimer's, while Eisai is both Biogen's Leqembi partner and a neuroscience peer. Roche and other large pharma compete across the wider neurology space.
Multiple sclerosis and rare neuromuscular
Roche (Ocrevus), Novartis, Sanofi, and generic/biosimilar makers pressure Biogen's MS franchise. In spinal muscular atrophy, Roche (Evrysdi) and Novartis (Zolgensma) compete with Spinraza.
Rare disease and retinal (post-Apellis)
In geographic atrophy, Astellas (Izervay) competes directly with the newly acquired Syfovre. Other large biotechs such as Vertex, Regeneron, and Alexion (AstraZeneca) compete across rare immune and blood disorders.
What stocks are similar to Biogen Inc. (BIIB)?
Other names that sit close to BIIB: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Biogen Inc. (BIIB)
There are three common ways to get BIIB exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (IBB, XBI), which spreads the position across many companies. Or build it into a focused thematic portfolio, so BIIB sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where BIIB fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Biogen Inc. (BIIB)
BIIB is a cash-generative biotech leaning on Leqembi, freshly acquired products and late-stage lupus data to offset a shrinking legacy base, so the thesis lives or dies on the new pipeline. Four straight earnings beats and a run to near its 52-week high mean expectations are higher than they were earlier in 2026.
More on Biogen Inc. (BIIB)
Whether BIIB is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BIIB a buy or a sell?, and where the stock could go from here in the BIIB stock forecast.
For income investors, whether BIIB pays a dividend and how the payout looks is covered in does BIIB pay a dividend? And to weigh BIIB against a peer, read the full side-by-side comparisons: BIIB vs VRTX and BIIB vs REGN.
Wondering how BIIB fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Biogen Inc.
Ask Walnut's AI anything about BIIB and see how it fits what you own.
FAQ
What does Biogen do?
+
Biogen is a biotechnology company focused on neuroscience and rare diseases, now expanding into immunology. Its products span multiple sclerosis (Tysabri, Tecfidera), the Alzheimer's drug Leqembi (with Eisai), spinal muscular atrophy (Spinraza), Friedreich's ataxia (Skyclarys), and, after the 2026 Apellis acquisition, retinal and rare-blood conditions.
Is BIIB a good investment?
+
That depends on your goals and risk tolerance, and Walnut is not an investment adviser. BIIB is a turnaround story: it still trades at a modest forward multiple (about 14 times), but its legacy revenue is declining, the shares have already risen about 66% over the past year, and the thesis rests on Leqembi, Apellis products and the lupus pipeline succeeding. Consider how much biotech and single-drug risk fits your portfolio.
Why is Biogen's revenue declining?
+
Its historic multiple sclerosis franchise faces generic competition for Tecfidera and biosimilar competition for Tysabri, and Spinraza faces newer SMA rivals. Biogen guided MS products excluding Vumerity down a mid-teen percentage in 2026. Total revenue has held up better than that because of Leqembi, Skyclarys and the Apellis products: Q2 2026 revenue grew about 3%, and analysts model about $10.4 billion for 2026, up from about $9.9 billion in 2025.
How important is Leqembi to Biogen?
+
Leqembi is the company's most important growth driver. Worldwide in-market sales were around $168 million in Q1 2026, up roughly 74 percent year over year. Biogen shares the economics with partner Eisai, and a subcutaneous maintenance version could widen adoption if reimbursement and uptake continue building.
What was the Apellis acquisition?
+
In 2026 Biogen acquired Apellis Pharmaceuticals for about $5.6 billion in cash plus a contingent value right tied to Syfovre sales. The deal added Syfovre (for geographic atrophy, a retinal disease) and Empaveli (for rare blood and kidney disorders), products that generated roughly $689 million in 2025.
How is BIIB valued?
+
As of October 16, 2026 Biogen had a market cap of about $35 billion, a share price near $236, a forward P/E of roughly 14 times and a trailing P/E near 42 times (GAAP earnings are depressed by deal-related charges). The average analyst target of about $244 is close to the current price after the 2026 rally.
Who are Biogen's main competitors?
+
In Alzheimer's, Eli Lilly (Kisunla) competes with Leqembi. In multiple sclerosis, Roche (Ocrevus), Novartis, and Sanofi apply pressure. In spinal muscular atrophy, Roche (Evrysdi) and Novartis (Zolgensma) compete with Spinraza, and Astellas (Izervay) rivals the acquired Syfovre in geographic atrophy.
Does Biogen pay a dividend?
+
No. Biogen has historically not paid a regular dividend, instead directing capital toward research, share buybacks, and acquisitions such as the 2026 Apellis deal. Investors seeking income would typically look elsewhere; the case for BIIB is capital appreciation from a successful pipeline transition.
How did Biogen do in its latest quarter?
+
In Q2 2026 Biogen grew revenue about 3% year over year and reported non-GAAP EPS of $3.60, far above the roughly $2.03 consensus. That made four straight quarters of beats, following $3.57 against $2.95 in Q1. Third-quarter results are scheduled for October 28, 2026, with consensus EPS of about $2.00 on revenue near $2.63 billion.
How has BIIB stock performed in 2026?
+
As of the October 16, 2026 close near $236.13, BIIB was up about 33% year to date and about 66% over one year, close to its 52-week high of about $241 and well above its 52-week low of $138. The latest leg came after J.P. Morgan upgraded the stock to Overweight on October 12, 2026 ahead of pipeline readouts.
Guides that feature BIIB
BIIB is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Biogen Inc.'s investor relations page or your broker before making investment decisions.